Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Indiva Reports Fiscal Year 2023 Results Including Record Positive EBITDA and Income (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Traws Pharma Inc TRAW

Healthcare
Traws Pharma, Inc., formerly Onconova Therapeutics, Inc., is a virology and oncology company. The Company is engaged in developing antivirals for influenza, COVID and other respiratory infections and narazaciclib. Its proprietary portfolio includes, TRX100 (viroksavir), TRX01 (travaltrevir), and Narazaciclib. Viroksavir is a cap-dependent endonuclease inhibitor for influenza. Travaltrevir is a... see more

Recent & Breaking News (NDAQ:TRAW)

Traws Pharma Announces New Employee Inducement Grants

GlobeNewswire April 2, 2024

Onconova Therapeutics, Inc. and Trawsfynydd Therapeutics, Inc. Announce Business Combination to Form Traws Pharma, Inc, a Best-in-Class Virology and Oncology Company

GlobeNewswire April 2, 2024

Onconova Therapeutics' Rigosertib Poster Selected for AACR 2024

GlobeNewswire March 8, 2024

Onconova Therapeutics' Narazaciclib ASH Poster Highlights Activity in Treatment Resistant Mantle Cell Lymphoma

GlobeNewswire December 12, 2023

Onconova Therapeutics' Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i's

GlobeNewswire December 8, 2023

Onconova Therapeutics to Present at NobleCon19, Noble Capital Markets' Nineteenth Annual Emerging Growth Equity Conference

GlobeNewswire November 28, 2023

Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results

GlobeNewswire November 14, 2023

Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023

GlobeNewswire November 7, 2023

Onconova Therapeutics' ASH Poster To Focus on Narazaciclib in MCL

GlobeNewswire November 2, 2023

Onconova Expands Leadership Team with Two Key Appointments

GlobeNewswire October 24, 2023

Promising Preclinical Narazaciclib Data Presented at MCL Meeting

GlobeNewswire October 19, 2023

Encouraging Rigosertib Data Presented at EADV as Late Breaker

GlobeNewswire October 12, 2023

Onconova Therapeutics to Present a Late-Breaking Abstract on Rigosertib at the 2023 EADV Congress

GlobeNewswire September 28, 2023

Onconova Therapeutics to Participate at the H.C. Wainwright 25th Annual Global Investment Conference

GlobeNewswire September 6, 2023

Onconova Therapeutics Reports Corporate Update and Announces Second Quarter 2023 Financial Results

GlobeNewswire August 10, 2023

Onconova Therapeutics to Provide Corporate Update and Announce Second Quarter 2023 Financial Results on August 10, 2023

GlobeNewswire August 3, 2023

Onconova Therapeutics Presents Preclinical Data on Narazaciclib at the 17th International Conference on Malignant Lymphoma

GlobeNewswire June 14, 2023

Onconova Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology Annual Meeting

GlobeNewswire June 5, 2023

Onconova Therapeutics Announces Dosing of First Participant in Investigator-Sponsored Phase 2 Trial of Rigosertib Plus Pembrolizumab in Metastatic Melanoma Patients Refractory to Immune Checkpoint Blockade

GlobeNewswire May 25, 2023

Onconova Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire May 15, 2023